Hallmarks of cancer: New dimensions
10.1158/2159-8290.cd-21-1059 · 2022
Spatially organized multicellular immune hubs in human colorectal cancer
10.1016/j.cell.2021.08.003 · 2021
Spatiotemporal analyses of the pan-cancer single-cell landscape reveal widespread profibrotic ecotypes associated with tumor immunity
10.1038/s43018-025-01039-5 · 2025
Intratumoral dendritic cell-CD4(+) T helper cell niches enable CD8(+) T cell differentiation following PD-1 blockade in hepatocellular carcinoma
10.1038/s41591-023-02345-0 · 2023
IGSF8 is an innate immune checkpoint and cancer immunotherapy target
10.1016/j.cell.2024.03.039 · 2024
IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer
10.1056/evidoa2200167 · 2023
Intratumoral oncolytic herpes virus G47Δ for residual or recurrent glioblastoma: A phase 2 trial
10.1038/s41591-022-01897-x · 2022
An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy
10.1038/s43018-024-00760-x · 2024
SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade
10.1038/s41586-025-09655-y · 2025
NK cells mediate clearance of CD8(+) T cell-resistant tumors in response to STING agonists
10.1126/sciimmunol.aaz2738 · 2020
CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma
10.1056/nejmoa1807315 · 2018
Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response
10.1016/j.immuni.2018.09.016 · 2018
Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections
10.1136/jitc-2022-005518 · 2023
DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response
10.1038/s41467-022-34041-x · 2022
Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity
10.1038/s41467-024-44789-z · 2024
cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity
10.1038/s41586-020-2611-3 · 2020
A distinct stimulatory cDC1 subpopulation amplifies CD8(+) T cell responses in tumors for protective anti-cancer immunity
10.1016/j.ccell.2023.06.008 · 2023
NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control
10.1016/j.cell.2018.01.004 · 2018
Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer
10.1016/j.cell.2022.02.021 · 2022
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants
10.1016/j.cell.2023.03.007 · 2023
Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia
10.1126/scitranslmed.abm1375 · 2022
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
10.1038/nature25501 · 2018
VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment
10.1172/jci.insight.150735 · 2021
Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma
10.1016/j.immuni.2024.04.006 · 2024
Spatially segregated macrophage populations predict distinct outcomes in colon cancer
10.1158/2159-8290.cd-23-1300 · 2024
Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models
10.1038/s41556-018-0256-3 · 2019
Non-cell-autonomous cancer progression from chromosomal instability
10.1038/s41586-023-06464-z · 2023
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
10.1038/s41591-020-0856-x · 2020
Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer
10.1016/j.ccell.2023.12.012 · 2024
Radiation-induced circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma
10.1126/scitranslmed.abn6758 · 2023
Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity
10.1016/j.ccell.2024.10.014 · 2024
STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma
10.1038/s41586-023-05880-5 · 2023
A conserved dendritic-cell regulatory program limits antitumour immunity
10.1038/s41586-020-2134-y · 2020
Unleashing type-2 dendritic cells to drive protective antitumor CD4(+) T cell immunity
10.1016/j.cell.2019.02.005 · 2019
Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma
10.1158/2159-8290.cd-21-0425 · 2021
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
10.1016/j.ccell.2024.10.007 · 2024
Transcriptional and functional analysis of CD1c(+) human dendritic cells identifies a CD163(+) subset priming CD8(+)CD103(+) T cells
10.1016/j.immuni.2020.06.002 · 2020
Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy
10.1038/s43018-023-00668-y · 2024
Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer
10.1016/j.immuni.2022.10.002 · 2022
Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape
10.1126/science.adg1955 · 2024
